See more : FingerTango Inc. (FGRTF) Income Statement Analysis – Financial Results
Complete financial analysis of BioAtla, Inc. (BCAB) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of BioAtla, Inc., a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- Delek Group Ltd. (DLEKG.TA) Income Statement Analysis – Financial Results
- DaChan Food (Asia) Limited (3999.HK) Income Statement Analysis – Financial Results
- Ojai Oil Company (OJOC) Income Statement Analysis – Financial Results
- Hawaiian Holdings, Inc. (HA) Income Statement Analysis – Financial Results
- The Lottery Corporation Limited (LTRCF) Income Statement Analysis – Financial Results
BioAtla, Inc. (BCAB)
About BioAtla, Inc.
BioAtla, Inc., a clinical stage biopharmaceutical company, develops specific and selective antibody-based therapeutics for the treatment of solid tumor cancer. Its lead product candidate is BA3011, a conditionally active biologic (CAB) antibody-drug conjugate (ADC) for soft tissue and bone sarcoma tumors, non-small cell lung cancer (NSCLC), and ovarian cancer. It also develops BA3021, a CAB ADC for multiple solid tumor types, including NSCLC, melanoma, and ovarian cancer; and BA3071, which is a CAB anti-cytotoxic T-lymphocyte-associated antigen 4 antibody for renal cell carcinoma, NSCLC, small cell lung cancer, hepatocellular carcinoma, melanoma, bladder cancer, gastric cancer, and cervical cancer. BioAtla, Inc. was founded in 2007 and is based in San Diego, California.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 |
|---|---|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 250.00K | 429.00K | 5.20M | 10.63M |
| Cost of Revenue | 103.73M | 1.20M | 1.33M | 19.93K | 25.92K | 26.31M |
| Gross Profit | -103.73M | -1.20M | -1.08M | 409.07K | 5.17M | -15.68M |
| Gross Profit Ratio | 0.00% | 0.00% | -432.00% | 95.35% | 99.50% | -147.53% |
| Research & Development | 103.73M | 79.35M | 58.27M | 19.93M | 25.92M | 26.31M |
| General & Administrative | 25.96M | 28.79M | 38.42M | 10.60M | 7.55M | 12.56M |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 25.96M | 28.79M | 38.42M | 10.60M | 7.55M | 12.56M |
| Other Expenses | 0.00 | 10.00K | 1.00K | -1.00K | -22.00K | -5.00K |
| Operating Expenses | 129.69M | 108.14M | 96.69M | 30.53M | 33.47M | 38.86M |
| Cost & Expenses | 129.69M | 108.14M | 96.69M | 30.53M | 33.47M | 38.86M |
| Interest Income | 6.31M | 1.65M | 350.00K | 100.00K | 128.00K | 209.00K |
| Interest Expense | 0.00 | 3.00K | 1.39M | 1.63M | 949.00K | |
| Depreciation & Amortization | 1.22M | 1.20M | 1.33M | 1.01M | 860.00K | 794.00K |
| EBITDA | -122.24M | -106.48M | -94.07M | -33.46M | -27.37M | -27.24M |
| EBITDA Ratio | 0.00% | 0.00% | -37,903.60% | -6,758.04% | -525.04% | -256.29% |
| Operating Income | -129.69M | -108.14M | -96.44M | -30.10M | -28.27M | -28.23M |
| Operating Income Ratio | 0.00% | 0.00% | -38,576.00% | -7,016.08% | -543.62% | -265.68% |
| Total Other Income/Expenses | 6.23M | 1.66M | 1.04M | -5.75M | -1.59M | -745.00K |
| Income Before Tax | -123.46M | -106.48M | -95.40M | -35.85M | -29.86M | -28.98M |
| Income Before Tax Ratio | 0.00% | 0.00% | -38,160.80% | -8,357.34% | -574.13% | -272.69% |
| Income Tax Expense | 0.00 | -1.20M | 4.00K | 1.39M | 1.55M | 204.00K |
| Net Income | -123.46M | -105.28M | -95.41M | -37.24M | -31.40M | -28.98M |
| Net Income Ratio | 0.00% | 0.00% | -38,162.40% | -8,680.89% | -603.88% | -272.69% |
| EPS | -2.58 | -2.70 | -2.76 | -1.11 | -0.93 | -1.34 |
| EPS Diluted | -2.58 | -2.70 | -2.76 | -1.11 | -0.93 | -1.34 |
| Weighted Avg Shares Out | 47.78M | 38.93M | 34.56M | 33.66M | 33.66M | 21.59M |
| Weighted Avg Shares Out (Dil) | 47.78M | 38.93M | 34.56M | 33.66M | 33.66M | 21.59M |
BioAtla, Inc. (BCAB) Q4 2023 Earnings Call Transcript
BioAtla, Inc. (BCAB) Q4 2023 Earnings Call Transcript
BioAtla Reports Fourth Quarter and Full Year 2023 Financial Results and Highlights Recent Progress
SAN DIEGO, March 26, 2024 (GLOBE NEWSWIRE) -- BioAtla, Inc. (Nasdaq: BCAB), a global clinical-stage biotechnology company focused on the development of Conditionally Active Biologic (CAB) antibody therapeutics for the treatment of solid tumors, today announced its financial results for...
BioAtla to Announce Fourth Quarter and Full-Year 2023 Financial Results and Provide Business Highlights on March 26, 2024
SAN DIEGO, March 19, 2024 (GLOBE NEWSWIRE) -- BioAtla, Inc. (Nasdaq: BCAB), a global clinical-stage biotechnology company focused on the development of Conditionally Active Biologic (CAB) antibody therapeutics for the treatment of solid tumors, today announced that it plans to...
BioAtla Announces Poster Presentations at the 2024 American Association for Cancer Research (AACR) Annual Meeting
SAN DIEGO, March 07, 2024 (GLOBE NEWSWIRE) -- BioAtla, Inc. (Nasdaq: BCAB), a global clinical-stage biotechnology company focused on the development of Conditionally Active Biologic (CAB) antibody therapeutics for the treatment of solid tumors, today announced preclinical poster presentations at...
BioAtla to Participate in the 42nd Annual J.P. Morgan Healthcare Conference
SAN DIEGO, Dec. 20, 2023 (GLOBE NEWSWIRE) -- BioAtla, Inc. (Nasdaq: BCAB), a global clinical-stage biotechnology company focused on the development of Conditionally Active Biologic (CAB) antibody therapeutics for the treatment of solid tumors, today announced that the Company's management...
BioAtla Hosting Virtual R&D Day to Highlight BA3071 CAB-CTLA-4 Phase 1 Data in Multiple Solid Tumor Types
Multiple confirmed responses and durable disease control observed Emerging differentiated safety profile enables further exploration at higher doses Ongoing Phase 2 clinical study of monotherapy and in combination with a PD-1 inhibitor SAN DIEGO, Dec. 13, 2023 (GLOBE NEWSWIRE) --...
BioAtla to Host Virtual R&D Day to Review BA3071 CAB-CTLA-4 Phase 1 Data in Multiple Solid Tumor Types on Wednesday, December 13, 2023
SAN DIEGO, Dec. 06, 2023 (GLOBE NEWSWIRE) -- BioAtla, Inc. (Nasdaq: BCAB), a global clinical-stage biotechnology company focused on the development of Conditionally Active Biologic (CAB) antibody therapeutics for the treatment of solid tumors, today announced it will host a...
BioAtla Presented Phase 2 Clinical Trial Data at the IASLC 2023 North America Conference on Lung Cancer and Virtual KOL Event
Results from the Phase 2 BA3011 clinical non-small cell lung cancer (NSCLC) study demonstrated promising clinical benefits in heavily pre-treated non-squamous histology patients across key endpoints
BioAtla to Participate in the JMP Securities Hematology and Oncology Summit
SAN DIEGO, Nov. 30, 2023 (GLOBE NEWSWIRE) -- BioAtla, Inc. (Nasdaq: BCAB), a global clinical-stage biotechnology company focused on the development of Conditionally Active Biologic (CAB) antibody therapeutics for the treatment of solid tumors, today announced that the Company's management...
BioAtla to Host Virtual KOL Event to Review IASLC Data on BA3011 in NSCLC
SAN DIEGO, Nov. 28, 2023 (GLOBE NEWSWIRE) -- BioAtla, Inc. (Nasdaq: BCAB), a global clinical-stage biotechnology company focused on the development of Conditionally Active Biologic (CAB) antibody therapeutics for the treatment of solid tumors, today announced it will host a...
Source: https://incomestatements.info
Category: Stock Reports